Struggling Adaptimmune gets a boost from the FDA as T-cell cancer drug wins an inside track at the agency

Adaptimmune has been struggling as of late, losing its R&D chief during a CEO transition as its share price $ADAP steadily drifted down to alarming lows. But the struggling biotech got a much-needed boost today from the FDA, which put one of its top cancer drugs on the inside track reserved for drugs that qualify as a Regenerative Medicine Advanced Therapy.